Literature DB >> 21160865

Treatment of colorectal carcinoids: A new paradigm.

Tsuyoshi Konishi1, Toshiaki Watanabe, Hirokazu Nagawa, Masatoshi Oya, Masashi Ueno, Hiroya Kuroyanagi, Yoshiya Fujimoto, Takashi Akiyoshi, Toshiharu Yamaguchi, Tetsuichiro Muto.   

Abstract

It is often difficult to evaluate the grade of malignancy and choose an appropriate treatment for colorectal carcinoids in clinical settings. Although tumor size and depth of invasion are evidently not enough to stratify the risk of this rare tumor, the present guidelines or staging systems do not mention other clinicopathological variables. Recent studies, however, have shed light on the impact of lymphovascular invasion on the outcome of colorectal carcinoids. It has been revealed that the presence of lymphovascular invasion was among the strongest risk factors for metastasis along with tumor size and depth of invasion. Furthermore, tumors smaller than 1 cm, within submucosal invasion and without lymphovascular invasion, carry minimal risk for metastasis with 100% 5-year survival in the studies from Japan as well as from the USA. This would suggest that these tumors could be curatively treated by endoscopic resection or transanal local excision. On the other hand, colorectal carcinoids with either lymphovascular invasion or tumor size larger than 1 cm carry the risk for metastasis equivalent to adenocarcinomas. Therefore, it should be emphasized that histological examination of lymphovascular invasion is mandatory in the specimens obtained by endoscopic resection or transanal local excision, as this would provide useful information for determining the need for additional radical surgery with regional lymph node dissection. Although the present guidelines or TNM staging system do not mention the impact of lymphovascular invasion, this would be among the next promising targets in order to establish better guidelines and staging systems, particularly in early-stage colorectal carcinoids.

Entities:  

Keywords:  Carcinoid; Colorectal cancer; Lymphovascular invasion; Neuroendocrine tumor

Year:  2010        PMID: 21160865      PMCID: PMC2999232          DOI: 10.4240/wjgs.v2.i5.153

Source DB:  PubMed          Journal:  World J Gastrointest Surg


  23 in total

1.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.

Authors:  J K Ramage; A H G Davies; J Ardill; N Bax; M Caplin; A Grossman; R Hawkins; A M McNicol; N Reed; R Sutton; R Thakker; S Aylwin; D Breen; K Britton; K Buchanan; P Corrie; A Gillams; V Lewington; D McCance; K Meeran; A Watkinson
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 2.  Epidemiology, tumour biology and histopathological classification of neuroendocrine tumours of the gastrointestinal tract.

Authors:  Günter Klöppel; Martin Anlauf
Journal:  Best Pract Res Clin Gastroenterol       Date:  2005-08       Impact factor: 3.043

3.  Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden.

Authors:  K Hemminki; X Li
Journal:  Cancer       Date:  2001-10-15       Impact factor: 6.860

4.  Tiny carcinoids may be malignant.

Authors:  F Seow-Cheoen; J Ho
Journal:  Dis Colon Rectum       Date:  1993-03       Impact factor: 4.585

Review 5.  Current status of gastrointestinal carcinoids.

Authors:  Irvin M Modlin; Mark Kidd; Igor Latich; Michelle N Zikusoka; Michael D Shapiro
Journal:  Gastroenterology       Date:  2005-05       Impact factor: 22.682

6.  Classification of low-grade neuroendocrine tumors of midgut and unknown origin.

Authors:  Susanne Van Eeden; Pascal F H J Quaedvlieg; Babs G Taal; G Johan A Offerhaus; Cornelis B H W Lamers; Marie-Louise F Van Velthuysen
Journal:  Hum Pathol       Date:  2002-11       Impact factor: 3.466

Review 7.  Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases.

Authors:  Jun Soga
Journal:  Cancer       Date:  2005-04-15       Impact factor: 6.860

8.  Does mesoappendix infiltration predict a worse prognosis in incidental neuroendocrine tumors of the appendix? A clinicopathologic and immunohistochemical study of 15 cases.

Authors:  Giulio Rossi; Riccardo Valli; Federica Bertolini; Pamela Sighinolfi; Luisa Losi; Alberto Cavazza; Francesco Rivasi; Gabriele Luppi
Journal:  Am J Clin Pathol       Date:  2003-11       Impact factor: 2.493

Review 9.  The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification.

Authors:  Günter Klöppel; Aurel Perren; Philipp U Heitz
Journal:  Ann N Y Acad Sci       Date:  2004-04       Impact factor: 5.691

10.  Endocrinocarcinomas (carcinoids and their variants) of the duodenum. An evaluation of 927 cases.

Authors:  J Soga
Journal:  J Exp Clin Cancer Res       Date:  2003-09
View more
  14 in total

Review 1.  Early Gastroenteropancreatic Neuroendocrine Tumors: Endoscopic Therapy and Surveillance.

Authors:  Hans Scherübl; Guillaume Cadiot
Journal:  Visc Med       Date:  2017-10-10

2.  Poorly-differentiated colorectal neuroendocrine tumour: CT differentiation from well-differentiated neuroendocrine tumour and poorly-differentiated adenocarcinomas.

Authors:  Ji Hee Kang; Se Hyung Kim; Joon Koo Han
Journal:  Eur Radiol       Date:  2017-02-16       Impact factor: 5.315

Review 3.  Is there any role for minimally invasive surgery in NET?

Authors:  M Thomaschewski; H Neeff; T Keck; H P H Neumann; T Strate; E von Dobschuetz
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

4.  Management of early gastrointestinal neuroendocrine neoplasms.

Authors:  Hans Scherübl; Robert T Jensen; Guillaume Cadiot; Ulrich Stölzel; Günter Klöppel
Journal:  World J Gastrointest Endosc       Date:  2011-07-16

5.  The Ki-67 labeling index and lymphatic/venous permeation predict the metastatic potential of rectal neuroendocrine tumors.

Authors:  Shinya Sugimoto; Kinichi Hotta; Tadakazu Shimoda; Kenichiro Imai; Yuichiro Yamaguchi; Takashi Nakajima; Takuma Oishi; Keita Mori; Kohei Takizawa; Naomi Kakushima; Masaki Tanaka; Noboru Kawata; Hiroyuki Matsubayashi; Hiroyuki Ono
Journal:  Surg Endosc       Date:  2015-12-30       Impact factor: 4.584

6.  A well differentiated neuroendocrine tumor of the jejunum with peritoneal carcinomatosis: A case report.

Authors:  Foteini Antoniadou; Dimitrios Korkolis; Nektarios Koufopoulos; Dimitrios Manatakis; Stratigoula Sakellariou
Journal:  Mol Clin Oncol       Date:  2018-10-04

7.  Long-term outcome of patients with locally resected high- and low-risk rectal carcinoid tumors.

Authors:  Kohei Shigeta; Koji Okabayashi; Hirotoshi Hasegawa; Yoshiyuki Ishii; Hiroki Ochiai; Masashi Tsuruta; Makio Mukai; Kaori Kameyama; Toshio Uraoka; Naohisa Yahagi; Yuko Kitagawa
Journal:  J Gastrointest Surg       Date:  2014-02-12       Impact factor: 3.452

8.  Evaluation of treatment for rectal neuroendocrine tumors sized under 20 mm in comparison with the WHO 2010 guidelines.

Authors:  Nobuhisa Matsuhashi; Takao Takahashi; Hiroyuki Tomita; Hiroshi Araki; Takashi Ibuka; Kaori Tanaka; Toshiyuki Tanahashi; Satoshi Matsui; Yoshiyuki Sasaki; Yoshihiro Tanaka; Naoki Okumura; Kazuya Yamaguchi; Shinji Osada; Kazuhiro Yoshida
Journal:  Mol Clin Oncol       Date:  2017-07-18

9.  Nonlinear optical microscopy for label-free detection of gastrointestinal neuroendocrine tumors.

Authors:  Lianhuang Li; Liwei Jiang; Zhifen Chen; Deyong Kang; Zhenrong Yang; Xing Liu; Weizhong Jiang; Shuangmu Zhuo; Guoxian Guan; Yongjian Zhou; Jianxin Chen
Journal:  Lasers Med Sci       Date:  2016-06-14       Impact factor: 3.161

10.  Long-Term Clinical Outcomes of Rectal Neuroendocrine Tumors According to the Pathologic Status After Initial Endoscopic Resection: A KASID Multicenter Study.

Authors:  Chang Mo Moon; Kyu Chan Huh; Sung-Ae Jung; Dong Il Park; Won Hee Kim; Hye Mi Jung; Seong-Joon Koh; Jin-Oh Kim; Yunho Jung; Kyeong Ok Kim; Jong Wook Kim; Dong-Hoon Yang; Jeong Eun Shin; Sung Jae Shin; Eun Soo Kim; Young-Eun Joo
Journal:  Am J Gastroenterol       Date:  2016-07-05       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.